Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Valneva ( (VALN) ) just unveiled an update.
On February 18, 2025, Valneva SE reported its preliminary unaudited financial results for 2024, indicating a successful year with a 10% increase in total revenues and a 13% rise in product sales revenue compared to 2023. The company ended 2024 with a strong cash position of €168.3 million, boosted by the sale of a Priority Review Voucher and a successful private placement. Looking ahead, Valneva anticipates continued revenue growth in 2025, with expected sales revenues of €170-180 million and total revenues reaching €180-190 million. The company aims to support strategic R&D investments while reducing operating cash burn. Key developments include progress in its Lyme disease program, securing regulatory approvals for its chikungunya vaccine, and advancing vaccine candidates for Shigella and Zika. Valneva’s strategic focus remains on commercial execution and scientific advancement, with several upcoming catalysts expected to drive significant value in 2025.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has successfully advanced multiple vaccines from early R&D to approvals. Valneva currently markets three proprietary travel vaccines, including the world’s first chikungunya vaccine, as well as certain third-party vaccines. Its growing commercial business revenues support the advancement of its vaccine pipeline, which includes the only Lyme disease vaccine candidate in advanced clinical development, a clinically advanced Shigella vaccine candidate, and vaccine candidates against the Zika virus and other global public health threats.
YTD Price Performance: 41.31%
Average Trading Volume: 60,372
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $576.2M
Find detailed analytics on VALN stock on TipRanks’ Stock Analysis page.
